Wearable Health Solutions (WHSI) 10-Q 22 May 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Mar. 31, 2023	May 22, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--06-30
Entity File Number	000-56368
Entity Registrant Name	WEARABLE HEALTH SOLUTIONS, INC.
Entity Central Index Key	0001443089
Entity Tax Identification Number	26-3534190
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	2901 W. Coast Highway
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Newport Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92663
City Area Code	949
Local Phone Number	270-7460
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,561,255,108

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Current Assets
Cash and cash equivalents	$ 16,341	$ 70,505
Accounts receivable, net	812	0
Due from related parties (See Footnote 11)	0	155,800
Accounts receivable, other	2,000	2,000
Inventory	33,281	7,064
Prepaid inventory	0	62,040
Total Current Assets	52,434	297,409
Property and Equipment
Property and equipment (net of $17,466 and $8,349 depreciation, as of March 31, 2023 and June 30, 2022, respectively)	41,976	41,651
Total Property and Equipment	41,976	41,651
Right-of-use assets	35,505	0
Total Assets	129,915	339,060
LIABILITIES and SHAREHOLDERS' DEFICIT
COMMITMENTS AND CONTINGENCIES (Note 12)
Current liabilities
Accounts payable	66,081	57,940
Accrued expenses and other current liabilities	446,650	374,278
Short-term lease liability	13,643	0
Related party debt, net	508,252	213,840
Deferred revenue	61,473	80,880
Line of credit	397,500	397,500
Notes payable	397,189	413,099
Note payable - other	50,000	50,000
Note payable - related party	170,000	170,000
Convertible notes – Leonite, net of debt discount of $46,371 and $-0-, respectively, and deferred debt issuance costs of $44,469 and $-0-, respectively	221,660	0
Convertible notes - other	673,750	673,750
Total current liabilities	3,006,198	2,431,287
Long-term lease liability	22,107	0
TOTAL LIABILITIES	3,028,305	2,431,287
Common stock
Common Stock: $0.0001 par value; 3,000,000,000 shares authorized,1,549,255,108 and 1,493,142,608 shares issued and outstanding as of March 31, 2023 and June 30, 2022, respectively	154,926	149,314
Common stock to be issued (98,242,500 and 35,602,500 shares as of March 31, 2023 and June 30, 2022, respectively)	814,555	407,677
Additional paid-in capital	37,365,081	36,773,035
Accumulated deficit	(41,234,081)	(39,423,382)
Total Shareholders’ Deficit	(2,898,390)	(2,092,227)
Total Liabilities and Shareholders’ Deficit	129,915	339,060
Series A Preferred Stock [Member]
SHAREHOLDERS’ DEFICIT
Preferred stock	1	1
Series B Preferred Stock [Member]
SHAREHOLDERS’ DEFICIT
Preferred stock	1	1
Series C Preferred Stock [Member]
SHAREHOLDERS’ DEFICIT
Preferred stock	684	684
Series D Preferred Stock [Member]
SHAREHOLDERS’ DEFICIT
Preferred stock	43	43
Series E Preferred Stock [Member]
SHAREHOLDERS’ DEFICIT
Preferred stock	$ 400	$ 400

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Depreciation	$ 17,466	$ 8,349
Net of debt discount	46,371	0
Debt issuance costs	$ 44,469	$ 0
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	1,549,255,108	1,493,142,608
Common stock, shares outstanding	1,549,255,108	1,493,142,608
Common stock to be issued	98,242,500	35,602,500
Series A Preferred Stock [Member]
Preferred stock, shares authorized	100,000	100,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	688	688
Preferred stock, shares outstanding	688	688
Series B Preferred Stock [Member]
Preferred stock, shares authorized	62,500	62,500
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	9,938	9,938
Preferred stock, shares outstanding	9,938	9,938
Series C Preferred Stock [Member]
Preferred stock, shares authorized	6,944,445	6,944,445
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	6,838,889	6,838,889
Preferred stock, shares outstanding	6,838,889	6,838,889
Series D Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	425,000	425,000
Preferred stock, shares outstanding	425,000	425,000
Series E Preferred Stock [Member]
Preferred stock, shares authorized	4,000,000	4,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	4,000,000	4,000,000
Preferred stock, shares outstanding	4,000,000	4,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 193,745	$ 212,982	$ 608,244	$ 819,601
Cost of sales	(135,207)	(111,434)	(354,627)	(457,307)
Gross profit	58,538	101,548	253,617	362,294
Operating expenses
Selling expense	33,784	44,346	304,066	318,708
Depreciation	3,286	2,500	9,117	5,849
Research and development expense	0	209,800	2,180	374,484
Consulting and professional fees	19,528	106,624	127,347	462,998
Insurance	35,557	28,124	92,075	50,507
Rent	4,080	4,050	16,270	12,555
Salaries and wages	358,386	6,974,610	1,215,671	10,904,649
Software expense	0	24,500	0	22,887
General and administrative	83,559	89,084	245,985	295,659
Total Operating expenses	538,180	7,483,638	2,012,711	12,448,296
Loss from operations	(479,642)	(7,382,090)	(1,759,094)	(12,086,002)
Other income / (expense), net
Change in fair value of derivative instrument	0	0	0	(213,053)
Gain on debt extinguishment	0	0	0	96,145
Gain on settlement of accounts payable	0	0	0	156,616
Other income	0	23,000	19,500	23,000
Interest income	0	0	1,500	0
Interest expense	(42,499)	(8,493)	(72,605)	(68,009)
Total other income (expense), net	(42,499)	14,507	(51,605)	(5,301)
Net loss before taxes	(522,141)	(7,367,583)	(1,810,699)	(12,091,303)
Income tax	0	0	0	0
Net loss	$ (522,141)	$ (7,367,583)	$ (1,810,699)	$ (12,091,303)

Consolidated Statements of Op_2

Consolidated Statements of Operations (Unaudited) (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Earnings Per Share, Basic	$ (0.00034)	$ (0.00731)	$ (0.00118)	$ (0.01487)
Earnings Per Share, Diluted	$ (0.00034)	$ (0.00731)	$ (0.00118)	$ (0.01487)
Weighted Average Number of Shares Outstanding, Basic	1,536,378,441	1,008,459,767	1,528,530,473	813,299,239
Weighted Average Number of Shares Outstanding, Diluted	1,536,378,441	1,008,459,767	1,528,530,473	813,299,239

Consolidated Statements of Shar

Consolidated Statements of Shareholders Deficit (Unaudited) - USD ($)	Preferred Stock Series A [Member]	Preferred Stock Series B [Member]	Preferred Stock Series C [Member]	Preferred Stock Series C To Be Issued [Member]	Preferred Stock Series D [Member]	Preferred Stock Series E [Member]	Preferred Stock Series E To Be Issued [Member]	Common Stock [Member]	Common Stock To Be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
As at December 31, 2022 at Jun. 30, 2021	$ 1	$ 1	$ 684	$ 0	$ 43	$ 190	$ 57,000	$ 64,708	$ 169,005	$ 22,732,295	$ (26,374,227)	$ (3,350,300)
Shares, Outstanding, Beginning Balance at Jun. 30, 2021	688	9,938	6,838,889	0	425,000	1,900,000	100,000	647,074,177	20,050,000
Loss for the period											(4,354,735)	(4,354,735)
Common stock for compensation								700	60,000	74,300		135,000
Common stock for debt conversion								2,527		250,166		252,693
Common stock for officer compensation									2,498			2,498
Preferred stock for compensation						200				2,999,800		3,000,000
Shares sold for cash – current quarter								$ 23,250	$ (100,000)	2,301,750		2,225,000
[custom:PreferredStockIssuedForCompensationShares]						2,000,000
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture								7,000,000	5,000,000
[custom:CommonStockIssuedForDebtConversionShares]								25,269,253
[custom:CommonStockIssuedForOfficerCompensationShares]									225,000
Stock Issued During Period, Shares, New Issues								232,500,000	(10,000,000)
As at March 31, 2023 at Sep. 30, 2021	$ 1	$ 1	$ 684	$ 0	$ 43	$ 390	$ 57,000	$ 91,185	$ 131,503	28,358,311	(30,728,962)	(2,089,845)
Shares, Outstanding, Ending Balance at Sep. 30, 2021	688	9,938	6,838,889	0	425,000	3,900,000	100,000	911,843,430	15,275,000
As at December 31, 2022 at Jun. 30, 2021	$ 1	$ 1	$ 684	$ 0	$ 43	$ 190	$ 57,000	$ 64,708	$ 169,005	22,732,295	(26,374,227)	(3,350,300)
Shares, Outstanding, Beginning Balance at Jun. 30, 2021	688	9,938	6,838,889	0	425,000	1,900,000	100,000	647,074,177	20,050,000
Loss for the period												(12,091,303)
As at March 31, 2023 at Mar. 31, 2022	$ 1	$ 1	$ 684	$ 0	$ 43	$ 400	$ 0	$ 108,049	$ 6,535,559	29,967,450	(38,465,530)	(1,853,343)
Shares, Outstanding, Ending Balance at Mar. 31, 2022	688	9,938	6,838,889	0	425,000	4,000,000	0	1,080,492,608	407,632,500
As at December 31, 2022 at Jun. 30, 2021	$ 1	$ 1	$ 684	$ 0	$ 43	$ 190	$ 57,000	$ 64,708	$ 169,005	22,732,295	(26,374,227)	(3,350,300)
Shares, Outstanding, Beginning Balance at Jun. 30, 2021	688	9,938	6,838,889	0	425,000	1,900,000	100,000	647,074,177	20,050,000
As at March 31, 2023 at Jun. 30, 2022	$ 1	$ 1	$ 684	$ 0	$ 43	$ 400	$ 0	$ 149,314	$ 407,677	36,773,035	(39,423,382)	(2,092,227)
Shares, Outstanding, Ending Balance at Jun. 30, 2022	688	9,938	6,838,889	0	425,000	4,000,000	0	1,493,142,608	35,602,500
As at December 31, 2022 at Sep. 30, 2021	$ 1	$ 1	$ 684	$ 0	$ 43	$ 390	$ 57,000	$ 91,185	$ 131,503	28,358,311	(30,728,962)	(2,089,845)
Shares, Outstanding, Beginning Balance at Sep. 30, 2021	688	9,938	6,838,889	0	425,000	3,900,000	100,000	911,843,430	15,275,000
Loss for the period											(368,985)	(368,985)
Common stock for compensation									2,422			2,422
Common stock for debt conversion								4,114		420,900		425,014
Preferred stock for compensation						10	(57,000)			56,990
Shares sold for cash – current quarter								9,750	200,000	965,250		1,175,000
Shares issued for services								1,000	(69,000)	68,000
Payment of subscription receivable										(100,000)		(100,000)
[custom:PreferredStockIssuedForCompensationShares]						100,000	(100,000)
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture									225,000
[custom:CommonStockIssuedForDebtConversionShares]								41,149,178
Stock Issued During Period, Shares, New Issues								97,500,000	20,000,000
Stock Issued During Period, Shares, Issued for Services								10,000,000	(10,000,000)
As at March 31, 2023 at Dec. 31, 2021	$ 1	$ 1	$ 684	$ 0	$ 43	$ 400	$ 0	$ 106,049	$ 264,925	29,769,450	(31,097,947)	(956,394)
Shares, Outstanding, Ending Balance at Dec. 31, 2021	688	9,938	6,838,889	0	425,000	4,000,000	0	1,060,492,608	25,500,000
Loss for the period											(7,367,583)	(7,367,583)
Common stock for compensation									6,470,634			6,470,634
Common stock for debt conversion
Preferred stock for compensation
Shares sold for cash – current quarter								2,000	(200,000)	198,000
Shares issued for services
Payment of subscription receivable
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture									402,132,500
Stock Issued During Period, Shares, New Issues								20,000,000	(20,000,000)
As at March 31, 2023 at Mar. 31, 2022	$ 1	$ 1	$ 684	$ 0	$ 43	$ 400	$ 0	$ 108,049	$ 6,535,559	29,967,450	(38,465,530)	(1,853,343)
Shares, Outstanding, Ending Balance at Mar. 31, 2022	688	9,938	6,838,889	0	425,000	4,000,000	0	1,080,492,608	407,632,500
As at December 31, 2022 at Jun. 30, 2022	$ 1	$ 1	$ 684	$ 0	$ 43	$ 400	$ 0	$ 149,314	$ 407,677	36,773,035	(39,423,382)	(2,092,227)
Shares, Outstanding, Beginning Balance at Jun. 30, 2022	688	9,938	6,838,889	0	425,000	4,000,000	0	1,493,142,608	35,602,500
Loss for the period											(748,767)	(748,767)
Common stock for compensation								500	(30,000)	65,500		36,000
Common stock for officer compensation								695	(101,262)	100,567
Shares sold for cash – current quarter									604,500			604,500
Shares issued for services								500		88,500		89,000
Payment of subscription receivable										30,000		30,000
Common stock to be issued for compensation									441			441
Common stock to be issued for officer compensation									47,144			47,144
Shares sold for cash – prior quarter								$ 2,150	$ (215,000)	212,850
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture								5,000,000	(2,000,000)
[custom:CommonStockIssuedForOfficerCompensationShares]								6,950,000	(6,950,000)
Stock Issued During Period, Shares, New Issues									67,950,000
Stock Issued During Period, Shares, Issued for Services								5,000,000
[custom:CommonStockToBeIssuedForCompensationShares]									32,500
[custom:CommonStockToBeIssuedForOfficerCompensationShares]									3,475,000
[custom:StockIssuedDuringPeriodValueNewIssuesPriorQuarterShares]								21,500,000	(21,500,000)
Fees incurred in connection with equity offering
Other
As at March 31, 2023 at Sep. 30, 2022	$ 1	$ 1	$ 684	$ 0	$ 43	$ 400	$ 0	$ 153,159	$ 713,500	37,270,452	(40,172,149)	(2,033,909)
Shares, Outstanding, Ending Balance at Sep. 30, 2022	688	9,938	6,838,889	0	425,000	4,000,000	0	1,531,592,608	76,610,000
As at December 31, 2022 at Jun. 30, 2022	$ 1	$ 1	$ 684	$ 0	$ 43	$ 400	$ 0	$ 149,314	$ 407,677	36,773,035	(39,423,382)	(2,092,227)
Shares, Outstanding, Beginning Balance at Jun. 30, 2022	688	9,938	6,838,889	0	425,000	4,000,000	0	1,493,142,608	35,602,500
Loss for the period												(1,810,699)
As at March 31, 2023 at Mar. 31, 2023	$ 1	$ 1	$ 684	$ 0	$ 43	$ 400	$ 0	$ 154,926	$ 814,555	37,365,081	(41,234,081)	(2,898,390)
Shares, Outstanding, Ending Balance at Mar. 31, 2023	688	9,938	6,838,889	0	425,000	4,000,000	0	1,549,255,108	98,242,500
As at December 31, 2022 at Sep. 30, 2022	$ 1	$ 1	$ 684	$ 0	$ 43	$ 400	$ 0	$ 153,159	$ 713,500	37,270,452	(40,172,149)	(2,033,909)
Shares, Outstanding, Beginning Balance at Sep. 30, 2022	688	9,938	6,838,889	0	425,000	4,000,000	0	1,531,592,608	76,610,000
Loss for the period											(539,791)	(539,791)
Common stock for compensation
Common stock for officer compensation
Shares sold for cash – current quarter									25,000			25,000
Shares issued for services
Payment of subscription receivable
Common stock to be issued for compensation									210			210
Common stock to be issued for officer compensation									22,422	49		22,471
Shares sold for cash – prior quarter
Commitment shares – Leonite convertible note									$ 49,936			49,936
Stock Issued During Period, Shares, New Issues									312,500
[custom:CommonStockToBeIssuedForCompensationShares]									32,500
[custom:CommonStockToBeIssuedForOfficerCompensationShares]									3,475,000
Fees incurred in connection with equity offering
Other
[custom:CommitmentSharesIssuedForConveribleNoteShares]									15,000,000
As at March 31, 2023 at Dec. 31, 2022	$ 1	$ 1	$ 684	$ 0	$ 43	$ 400	$ 0	$ 153,159	$ 811,068	37,270,501	(40,711,940)	(2,476,083)
Shares, Outstanding, Ending Balance at Dec. 31, 2022	688	9,938	6,838,889	0	425,000	4,000,000	0	1,531,592,608	95,430,000
Loss for the period											(522,141)	(522,141)
Common stock for compensation
Common stock for officer compensation								266	(22,846)	22,580
Shares sold for cash – current quarter									10,000			10,000
Shares issued for services								1,500		73,500		75,000
Payment of subscription receivable
Common stock to be issued for compensation
Common stock to be issued for officer compensation									16,333			16,333
Shares sold for cash – prior quarter
Commitment shares – Leonite convertible note
[custom:CommonStockIssuedForOfficerCompensationShares]								2,662,500	(2,662,500)
Stock Issued During Period, Shares, New Issues									2,000,000
Stock Issued During Period, Shares, Issued for Services								15,000,000
[custom:CommonStockToBeIssuedForOfficerCompensationShares]									3,475,000
Fees incurred in connection with equity offering										(1,500)		(1,500)
Other								1				1
As at March 31, 2023 at Mar. 31, 2023	$ 1	$ 1	$ 684	$ 0	$ 43	$ 400	$ 0	$ 154,926	$ 814,555	$ 37,365,081	$ (41,234,081)	$ (2,898,390)
Shares, Outstanding, Ending Balance at Mar. 31, 2023	688	9,938	6,838,889	0	425,000	4,000,000	0	1,549,255,108	98,242,500

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flow from operating activities
Net loss	$ (1,810,699)	$ (12,091,303)
Adjustment for non-cash charges and other items:
Depreciation	9,117	5,849
Amortization of deferred debt issuance costs	15,467	0
Stock-based compensation expense	286,600	9,610,554
Change in fair value of derivative instrument	0	213,053
Gain on debt extinguishment	0	(96,145)
Gain on settlement of accounts payable	0	(156,616)
Amortization of debt discount	16,129	0
Total adjustments	(1,483,386)	(2,514,608)
Changes in working capital
Decrease / (increase) in accounts receivable	(812)	25,694
Decrease / (increase) in inventory	(26,217)	0
Decrease / (increase) in prepaid inventory	62,040	0
Decrease / (increase) in prepaid expenses	0	16,485
(Decrease) / increase in trade and other payables	8,141	(67,992)
(Decrease) / increase in accrued expenses	72,617	99,393
(Decrease) / increase in accrued expenses - related party	225,047	(204,121)
(Decrease) / increase in deferred revenue	(19,407)	(25,992)
Total changes in working capital	321,409	(156,533)
Cash flow used in operating activities	(1,161,977)	(2,671,141)
Cash flow from investing activities
Purchase of property and equipment	(9,442)	(50,000)
Cash flow used in investing activities	(9,442)	(50,000)
Cash flow from financing activities
Proceeds from note payable	0	25,000
Proceeds received from related parties	225,165	0
Proceeds from issuance of convertible notes	240,000	0
Proceeds from issuance of stock for cash	669,500	3,300,000
Repayments of note payable	(15,910)	(825,864)
Fees paid in connection with equity offerings	(1,500)	0
Payments to related parties	0	(55,452)
Cash flow provided by financing activities	1,117,255	2,443,684
Decrease in cash and cash equivalents	(54,164)	(277,457)
Cash and cash equivalents at the beginning of the period	70,505	847,430
Cash and cash equivalents at end of the period	16,341	569,973
Non-Cash Investing and Financial Activities:
Conversions of notes and accrued interest	0	269,954
Interest	8,382	0
Taxes	$ 0	$ 0

Nature and Continuance of Opera

Nature and Continuance of Operations	9 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature and Continuance of Operations	Note 1 – Nature and Continuance of Operations Wearable Healthcare Solutions Inc. (the Company) was incorporated as Medical Alarm Concepts Holding, Inc. on June 4, 2008, under the laws of the State of Nevada. The Company was formed for the sole purpose of acquiring all of the membership units of Medical Alarm Concepts LLC, a Pennsylvania limited liability company (“Medical LLC”). On May 26, 2016, the Company filed an Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to change its name from “Medical Alarm Concepts, Inc.” to “Wearable Health Solutions, Inc.” The Company provides mobile health (mHealth) products and services to be used by customers in case of an emergency. As a provider of personal emergency devices, the Company provides innovative wearable healthcare products, tracking services, and turn-key solutions that enable our users to be proactive with their health, as well as safe and protected. The Company’s flagship products are the iHelp devices, the 3G and the next generation iHelp MAX™ – personal emergency alarm that are used to summon help in the event of an emergency at home. Basis of presentation The accompanying interim consolidated financial statements are unaudited, but in the opinion of management of Wearable Healthcare Solutions, Inc. (the Company), contain all adjustments, which include normal recurring adjustments, necessary to present fairly the financial position at March 31, 2023, and the results of operations and changes in shareholders’ deficit for the three and nine months ended March 31, 2023 and cash flows for the nine months ended March 31, 2023. The balance sheet as of June 30, 2022, is derived from the Company’s audited financial statements. Certain information and footnote disclosures normally included in financial statements that have been prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, although management of the Company believes that the disclosures contained in these financial statements are adequate to make the information presented therein not misleading. For further information, refer to the financial statements and the notes thereto included in the Company’s Annual Report on this Form 10-K for the fiscal year ended June 30, 2022. The results of operations for the three and nine months ended March 31, 2023, are not necessarily indicative of the results of operations to be expected for the full fiscal year ending June 30, 2023.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Principles of Consolidation Use of Estimates Cash and Cash Equivalents Accounts Receivable 24,517 0 23,705 0 Software Development for internal use 50,000 5 Concentration of Credit Risk Recognition of Revenues Recognition of Revenues The Company’s revenues are derived principally from utilizing new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with medical or age-related conditions. The Company recognizes revenue when it is realized or realizable and earned. For hardware sales, the Company recognizes revenues at a point in time when the product is shipped. Customers are billed on Net 30 terms. For service revenue, the Company recognizes revenues over the term of the service contract and when the services are rendered. For customers who pay several months at a time, the Company records revenues for the month’s services and the balance of funds to deferred revenues, and records the balance of revenues as they become current. Schedule of revenues 3 months ended March 31, 9 months ended March 31, REVENUES 2023 2022 2023 2022 Hardware revenue $ 31,476 $ 5,659 $ 82,201 $ 82,644 Service revenue 162,269 207,323 526,043 736,957 TOTAL REVENUES $ 193,745 $ 212,982 $ 608,244 $ 819,601 The following table discloses changes in unearned revenue for the nine months ended March 31, 2023 and 2022: Schedule of unearned revenue 2023 2022 Balance at beginning of period - June 30, $ 80,880 $ 108,298 Deferred revenue 120,688 168,823 Recognition of unearned revenue (140,095 ) (194,815 ) Balance at the end of the period - March 31, $ 61,473 $ 82,306 Deferral of revenues at March 31, 2023 and March 31, 2022 was $ 61,473 82,306 Deferred Taxes ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information. A tax position that meets this more-likely-than-not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority. The Federal and state income tax returns of the Company for 2022, 2021, and 2020 are subject to examination by the Internal Revenue Service and state taxing authorities for three (3) years from the date filed. Fair value of financial instruments Level 1 Level 2 Level 3 From time to time, our financial instruments include cash, accounts payable and accrued expenses, convertible notes, lines of credit, and credit cards. Research and Development 0 2,180 209,800 374,484 Basic and Diluted Loss per Common Share Schedule of anti-dilutive shares Basis of conversion Dilution 2023 2022 Series A Convertible 688 shares outstanding 1 share A: 2 shares 1,376 1,376 Series B Convertible 9,938 shares outstanding 1 share B: 2 shares 19,876 19,876 Series C Convertible 6,838,889 shares outstanding 1 share C: 10 shares 68,388,890 68,388,890 Series D Convertible 425,000 shares outstanding 1 share D: 10 shares 4,250,000 4,250,000 Series E Convertible 4,000,000 shares outstanding 1 share E: 100 shares 400,000,000 400,000,000 472,660,142 472,660,142 The Company has incurred losses for the past two years, as a result, the basic and diluted share bases will be presented as the same. For the three-month periods ended March 31, 2023 and 2022, the Company incurred losses of ($0.00034) and ($0.00731) per basic share and diluted share, respectively. For the nine months ended March 31, 2023 and 2022, the Company incurred losses of ($0.00118) and ($0.01487) per basic share and diluted share, respectively. Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes. The update is intended to simplify the current rules regarding the accounting for income taxes and addresses several technical topics including accounting for franchise taxes, allocating income taxes between a loss in continuing operations and in other categories such as discontinued operations, reporting income taxes for legal entities that are not subject to income taxes, and interim accounting for enacted changes in tax laws. The new standard is effective for fiscal years beginning after December 15, 2020; however, early adoption is permitted. The Company does not expect the adoption of this standard have a material impact on the consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Among other potential impacts, this change is expected to reduce reported interest expense, increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from shareholders’ equity to liabilities as it relates to the Company’s convertible senior notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS), which is consistent with the Company’s accounting treatment under the current standard. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. The Company early adopted the ASU on July 1, 2022, the beginning of its fiscal year. The Company reviewed all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC, and they did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Going Concern

Going Concern	9 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 3 – Going Concern The accompanying consolidated financial statements for the three and nine months ended March 31, 2023 and 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As at March 31, 2023 and June 30, 2022, the Company has shown losses for the last two years and has an accumulated deficit of ($ 41,234,081 39,423,382 During the nine months ended March 31, 2023, the Company has net cash used in operating activities of $ 1,161,977 286,600 1,810,699 1,117,255 2,953,764 Management believes that the Company’s capital requirements will depend on many factors including the success of the Company’s development efforts and its efforts to raise capital. Management also believes the Company needs to raise additional capital for working capital purposes. There can be no assurance that the Company will be able to obtain the additional capital resources necessary to implement its business plan or that any assumptions relating to its business plan will prove accurate. These factors raise substantial doubt about our ability to continue as a going concern for a period of 12 months from the issue date of this report. The consolidated financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Inventory, Prepaid Inventory, a

Inventory, Prepaid Inventory, and Prepaid Expenses	9 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventory, Prepaid Inventory, and Prepaid Expenses	Note 4 – Inventory, Prepaid Inventory, and Prepaid Expenses The Company maintains some inventory in its warehouse and purchases some of its inventory overseas. Inventories, except for stock in transit, are stated at lower of cost and net realizable value. Stock in transit is valued at cost comprising invoice value plus other charges thereon. Net realizable value is the estimated selling price in ordinary course of business less estimated costs of completion and selling expenses. The quantity of inventory may vary from time to time depending on the delivery schedule of overseas shipments. As of March 31, 2023 and June 30, 2022, the Company had $ 33,281 7,064 0 62,040 As of March 31, 2023 and June 30, 2022, the Company had $- 0 0

Property and Equipment

Property and Equipment	9 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 5 – Property and Equipment The Company has $20,000 in furnishings, $19,689 in office computers and equipment, and capitalized software development costs of $45,900 which are fully depreciated. On August 30, 2021, the Company purchased its dealer portal for $50,000 for internal use, amortized over 60 months. On September 26, 2022, the Company purchased used furniture for $ 9,442 36 As of March 31, 2023 and June 30, 2022, the Company recorded $ 41,976 41,651 Schedule of property, plant and equipment March 31, 2023 June 30, 2022 Furniture $ 29,442 $ 20,000 Office computers, equipment, software 19,689 19,689 Software development costs 45,900 45,900 Dealer Portal 50,000 50,000 Property, plant, and equipment 145,031 135,589 Less accumulated depreciation (103,055 ) (93,938 ) Net property, plant, and equipment $ 41,976 $ 41,651

Accounts payable and accrued ex

Accounts payable and accrued expenses and liabilities	9 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Accounts payable and accrued expenses and liabilities	Note 6 – Accounts payable and accrued expenses and liabilities The Company recorded Accounts Payable of $ 66,081 57,940 Accrued expenses and other current liabilities are expenses that have been incurred but not yet paid, and mainly include legal fees, audit fees and other professional fees as well as accrued interest in connection with the credit line and notes payable. The Company recorded $ 446,650 374,278

Notes Payable and Note payable-

Notes Payable and Note payable-other	9 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Notes Payable and Note payable-other	Note 7 – Notes Payable and Note payable-other Notes payable consists of notes payable from our subsidiary, notes payable-other, convertible notes payable, notes payable for stock purchases under Reg A, short term notes payable, and notes payable-BOAPIN portal, as follows: Schedule of short term notes payable March 31, 2023 June 30, 2022 Notes from subsidiary $ 158,333 $ 174,243 Notes payable – Reg A deposits 138,856 138,856 Short term bridge loan 100,000 100,000 Total Notes Payable $ 397,189 $ 413,099 Notes Payable - subsidiary The Company has various loans and credit lines outstanding. The credit line carries an interest rate of 6.24 9.24 10.90 Schedule of notes payable March 31, 2023 June 30, 2022 Wells Fargo Loan $ 8,770 $ 8,770 On Deck Loan 139,569 139,569 Susquehanna Salt Loan – 10,500 Prosper Loans 9,994 9,994 Marcus Loan – 5,410 Total Notes from Subsidiary (See Table Above) $ 158,333 $ 174,243 Short term bridge loan - COHEN On July 31, 2020, the Company secured a $ 500,000 12 12 On August 19, 2021, the Company repaid $ 300,000 100,000 At March 31, 2023 and June 30, 2022, the Company recorded a short term note payable of $ 100,000 3,000 9,000 3,000 18,649 85,677 76,677 Note payable – stock purchases under Reg A In March 2021 and June 2021, the Company accepted payments of $ 115,000 20,000 In October 2021, the Company accepted a loan of $ 5,000 At March 31, 2023 and June 30, 2022, the Company has recorded $ 138,856 138,856 2,700 8,100 2,700 8,736 20,407 12,307 Note Payable – Other In November, 2016, the Company secured a $ 50,000 4 1,000,000 4 During the three and nine months ended March 31, 2023, the Company recorded interest expense of $ 500 1,500 500 1,000 12,782 11,282 Convertible note payable – BENZA, D2CF On March 1, 2016 and March 3, 2016, the Company closed a private placement of debt and received an aggregate of $ 612,500 13,750 660,000 The Company is currently in negotiations to settle the $ 660,000 As of March 31, 2023 and June 30, 2022, the Company reported $ 673,750 673,750 Convertible Note – Leonite Capital, LLC On December 5, 2022, the Company, (the “Borrower”), received $ 250,000 1,000,000 62,500 March 5, 2024 10,839 34,722 15,000,000 78,000 28,064 10,000 59,936 11,987 15,467 12,500 16,129 10 0.007 Credit line – MediPendant New York Inc. On September 30, 2014, our subsidiary entered into a line of credit with Medi Pendant New York, Inc. (“MNY”), which is partially owned by a principal of its subsidiary. Under the line of credit agreement, the Company will be able to borrow up to $500,000 with the rate of interest of 6.5 500,000 As of March 31, 2023 and June 30, 2022, the Company has recorded $ 397,500 397,500 Debt settlement – On Deck, Susquehanna, MCA Cure In 2019, our subsidiary engaged MCA CURE to negotiate settlements with two creditors: On Deck and Susquehanna Salt, noted in the table above. The Company ceased paying the loan payments and paid to MCA Cure $ 43,875 47,000 90,875 0 0 139,569 139,569 0 10,500

Shareholders_ Deficit

Shareholders’ Deficit	9 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Shareholders’ Deficit	Note 10 – Shareholders’ Deficit Preferred Stock: The Company is currently authorized to issue 25,000,000 0.0001 Series A Convertible Preferred Stock 0.0001 Series B Convertible Preferred Stock 0.0001 Series C Convertible Preferred Stock 0.0001 The Company issued 6,700,003 shares for the BOAPIN asset purchase; these shares were issued on September 1, 2020. As of March 31, 2023 and June 30, 2022, 6,838,889 shares of Series C Convertible Preferred Stock were issued and outstanding, respectively. Series D Convertible Preferred Stock : Series E Convertible Preferred Stock : 0.0001 During the year ended June 30, 2021, as part of the change in control, 4,000,000 shares were returned to treasury to be canceled. In December 2020 the Company issued 1,000,000 shares of Series E Convertible Preferred Stock accrued in the prior year and issued 450,000 shares of Series E Convertible Preferred Stock to each of its two directors, 900,000 shares total, valued at $513,000 or $0.57 per share, accrued 100,000 shares of Series E Preferred stock to be issued to directors for services, valued at $57,000 or $.57 per share, all pricing based on the conversion of one share of Series E Convertible Preferred Stock for 100 shares of common stock and the price of the common stock on the date of accrual. During the year ended June 30, 2022, the Company issued 1,000,000 As of March 31, 2023 and June 30, 2022, 4,000,000 4,000,000 Common Stock The Company is currently authorized to issue 3,000,000,000 0.0001 During the nine months ended March 31, 2023, the Company issued 9,612,500 shares to its officers as compensation (of which 8,825,000 shares were granted in a prior period), valued at $124,108 or $.0129 per share; 5,000,000 shares to an employee as compensation, valued at $66,000 or $0.0132 per share; 21,500,000 shares issued to investors, valued at $215,000 or $0.01 per share; and 20,000,000 shares issued for services, valued at $164,000 or $0.0082 per share. All shares were recorded at the stock price of the date of agreement or grant. During the nine months ended March 31, 2023, the Company also recorded shares to be issued of 10,425,000 to its officers as compensation, valued at $85,949 or $.0082 per share, and shares to be issued of 65,000 to an employee as compensation, valued at $651 or $0.0100 per share. In addition, the Company recorded commitment shares to be issued of 15,000,000 valued at $78,000 or $0.0052 per share to Leonite Capital LLC in connection with the issuance of convertible notes on December 5, 2022. All shares were recorded at the stock price of the date of agreement or grant. During the nine months ended March 31, 2023, the Company received proceeds totaling $639,500 in connection with the issuance of 70,262,500 shares of common stock. Of the total proceeds received, $325,000 in proceeds was received from the issuance of 37,812,500 common shares that were issued under the terms of subscription agreements at the contract price of $0.008. Proceeds of $304,500 were received from the issuance of 30,450,000 common shares that were issued under the terms of subscription agreements at the contract price of $0.01, and proceeds of $10,000 was received from the issuance of 2,000,000 common shares that were issued under the terms of a subscription agreement at the contract price of $0.005. These shares are yet to be issued as of March 31, 2023. For the nine months ended March 31, 2022, the Company issued 7,000,000 common shares to employees and contractors for contractual bonuses, valued at $ 75,000 As of March 31, 2023 and June 30, 2022, the Company has 1,549,255,108 1,493,142,608

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 11 – Related Party Transactions Note payable – BOAPIN purchase In August 2020, and effective as of June 30, 2020, the Company purchased the BOAPIN portal, including all software, licensing, and ownership rights from Hypersoft Ventures, Inc., a related party through common ownership, for $800,200, which includes six million seven hundred thousand three (6,700,003) shares of Series C Convertible Preferred stock, valued at $375,200 or $0.056 per share, based on the conversion of one share of Series C Preferred stock for 10 shares of common stock and the stock price on the date of the transaction, and a note payable for $425,000, bearing eight percent (8%) interest with no prepayment or delinquency clauses. As of March 31, 2023 and June 30, 2022, the Company has recorded a Note payable-BOAPIN of $ 170,000 170,000 3,353 10,209 6,521 15,090 59,624 49,415 Related party debt, net From time to time, the Company received funds from related parties for day-to-day operations. These are short-term loans which bear no interest, and the Company expects to repay these loans by the end of the fiscal year following the year in which the short-term loan was made. The following table reflects the composition of the related party debt, net balance at March 31, 2023 and June 30, 2022. The Company had a receivable from certain management employees totaling $155,800 at June 30, 2022. The total receivable balance was subsequently collected by the Company on September 27, 2022. Schedule of related party transactions March 31, June 30, 2023 2022 Related parties – subsidiary $ 177,320 $ 202,875 Due from related parties – (155,800 ) Accrued salaries, bonus, fees 330,932 10,965 Total loans from related parties, net $ 508,252 $ 58,040

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Note 12 – Commitments and contingencies Legal Matters From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. 1) Wearable Health Solutions, Inc. v. Barry Honig, GRQ Consultants Inc., Benza Pharma LLC and John Does 1-10, Supreme Court of the State of New York County of New York, July 22, 2021. Company is disputing the validity of Notes from 3/2016 and seeking damages, reparations, and related costs. 2) GRQ Consultants, Inc. v. Wearable Health Solutions, Inc., Supreme Court of the State of New York, County of New York, August 26, 2021, Parties are seeking summary judgment of $50,000 plus accrued interest in response to lawsuit by Company regarding $50,000 loan from 11/2016. 3) Benza Pharma LLC, Sandor Capital, LP, and John Lemak v. Wearable Health Solutions, Inc., District Court, Clark County, Nevada, Parties are seeking summary judgment of $3,000,000 plus accrued interest in regards to convertible notes payable from March, 2016. The Company believes that there is a very low probability that it will pay this amount and as a result has not accrued for it on the Company’s balance sheet. On February 3, 2023, the plaintiffs in the case of Sandor Capital, LP and John Lemak v. Wearable Health Solutions, Inc., informed the Company that they would be discontinuing their legal action against the Company. 4) Medical Alarm Concepts LLC v. MCA Cure, LLC, Superior Court of New Jersey, Law Division, Morris County. Company is seeking return of payments for non-performance plus attorney fees and court costs. A settlement was reached between the parties whereby MCA Cure will pay an initial $10,000 and $6,500 each month until debt is satisfied in 2023 (See Note 14). Commitments and Contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.

Office_Warehouse lease

Office/Warehouse lease	9 Months Ended
	Mar. 31, 2023
Officewarehouse Lease
Office/Warehouse lease	Note 13 – Office/Warehouse lease In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the current accounting for leases and while retaining two distinct types of leases, finance and operating, (1) requires lessees to record a right of use asset and a related liability for the rights and obligations associated with a lease, regardless of lease classification, and recognize lease expense in a manner similar to current accounting, (2) eliminates most real estate specific lease provisions, and (3) aligns many of the underlying lessor model principles with those in the new revenue standard. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. For public companies, the new standard is effective for annual and interim periods in fiscal years beginning after December 15, 2018. For all other entities, including emerging growth companies, this standard is effective for annual reporting periods beginning after December 15, 2019, and interim periods within fiscal years beginning after December 2020. The Company maintains its corporate office at 2901 W. Coast Highway, Suite 200, Newport Beach, CA 92663. The Company currently pays $175 a month for its office space and the term is month-to-month. The Company’s subsidiary maintained a warehouse office in Pennsylvania to facilitate inventory arrival and product shipment. The three-year lease at $1,100 per month expired on September 30, 2021, and was renewed for 12 months at $1,300 per month beginning October 1, 2021 and expiring on September 30, 2022. The subsidiary subsequently entered into a month-to-month arrangement with this office warehouse and then terminated the arrangement and vacated the facility as of December 31, 2022. The Company entered into a new three-year lease agreement on September 9, 2022 for new warehouse space located in Mequon, Wisconsin. The monthly rent for this new warehouse space is currently $1,325 per month for the first twelve months of the lease agreement. Expenditures for the nine months ending March 31, 2023 and March 31, 2022 are as follows: Schedule lease cost 2023 2022 Rent expense $ 16,270 $ 12,555 The Company leased a fulfillment center in the U.S., which was classified as an operating lease which subsequently expired on September 30, 2022. The Company determines if an arrangement qualifies as a lease at the lease inception. Operating lease liabilities are recorded based on the present value of the future lease payments over the lease term, assessed as of the commencement date. The Company’s real estate leases, which are for a fulfillment center, generally have a lease term between 3 5 The Company’s lease agreements generally do not specify an implicit borrowing rate, and as such, the Company utilizes its incremental borrowing rate by lease term, in order to calculate the present value of the future lease payments. The discount rate represents a risk-adjusted rate on a secured basis, and is the rate at which the Company would borrow funds to satisfy the scheduled lease liability payment streams commensurate with the lease term. The Company’s lease agreement for its warehouse space located in King of Prussia, Pennsylvania expired on September 30, 2022. The Company has terminated the month-to-month arrangement and has vacated the warehouse located in King of Prussia, Pennsylvania as of December 31, 2022. As a result, the Company entered into a new three-year lease agreement on September 9, 2022 for new warehouse space located in Mequon, Wisconsin. The monthly rent which commenced in September 2022 is $1,325 per month and increases approximately 3% annually thereafter. The discount rate used was determined based on the available data as of the lease commencement date. The Right-of-use (“ROU”) asset value added as a result of this new lease agreement was $ 43,058 Certain of the Company’s lease agreements, primarily related to real estate, include options for the Company to either renew (extend) or early terminate the lease. Leases with renewal options allow the Company to extend the lease term typically between 1 and 3 years. Renewal options are reviewed at lease commencement to determine if such options are reasonably certain of being exercised, which could impact the lease term. When determining if a renewal option is reasonably certain of being exercised, the Company considers several factors, including but not limited to, significance of leasehold improvements incurred on the property, whether the asset is difficult to replace, or specific characteristics unique to the particular lease that would make it reasonably certain that the Company would exercise such option. In most cases, the Company has concluded that renewal and early termination options are not reasonably certain of being exercised by the Company (and thus not included in the Company’s ROU asset and lease liability) unless there is an economic, financial or business reason to do so. For the nine months ended March 31, 2023, total operating lease cost was $ 16,270 Schedule of future lease payments Fiscal Year Ending June 30, 2023 $ 3,975 2024 16,250 2025 16,670 July & August 2025 2,790 Total future minimum lease payments 39,685 Less imputed interest (3,935 ) Total present value of future minimum lease payments $ 35,750 Schedule of balance sheet related leases As of March 31, 2023 Operating lease right-of-use assets $ 35,505 Accrued lease liability 13,643 Long-term lease liability 22,107 $ 35,750 As of March 31, 2023 Weighted Average Remaining Lease Term 2.42 Weighted Average Discount Rate 8.44

Other income - settlement

Other income - settlement	9 Months Ended
	Mar. 31, 2023
Other Income and Expenses [Abstract]
Other income - settlement	Note 14 – Other income - settlement Settlement In 2019, the Company engaged MCA Cure to negotiate settlements with two note holders, and paid MCA Cure a total of $97,625. In 2020, the Company discovered MCA Cure had not performed when bank accounts were levied for $33,705 and $18,705, being subsequently refunded, and engaged an attorney to recover funds. Currently the Company has a settlement agreement in place with Susquehanna Salt Loan and has hired an attorney to recover funds and damages from MCA Cure. In February 2022, a settlement was reached with MCA Cure for fees and attorney costs of $ 105,125 For the nine months ended March 31, 2023 and 2022, the Company recorded $ 19,500 0

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 15 – Subsequent Events The Company evaluated events that have occurred after the balance sheet date but before the financial statements are issued and determined that there are no material events that are required to be disclosed. On April 4, 2023, the Company issued 2,000,000 shares valued at $24,000 or $0.012 per share to a computer consultant. These shares were previously accrued for by the Company in a prior period and are included in the Company’s balance sheet line item labeled “Common stock to be issued” at March 31, 2023. These shares were recorded at the stock price of the date of agreement or grant. On May 5, 2023, the Company received $50,000 in proceeds from the issuance of 10,000,000 shares at $0.005 pursuant to the Reg A offering terms and conditions. The Company incurred $8,000 in legal fees related to this transaction. On May 10, 2023, the Company entered into a severance and settlement agreement with Jennifer Loria, the Company’s former Chief Operating Officer of its wholly-owned subsidiary Medical Alarm Concepts LLC. The severance and settlement agreement includes payments totaling $35,000 for accrued bonus which will be paid in seven (7) monthly installments at $5,000 per installment. In addition, the Company will also pay severance of $15,000 over a three (3) month period of $5,000 per month and $15,000 in legal fees also payable in three monthly installments of $5,000. Lastly, the Company will reimburse Ms. Loria on a monthly basis for her medical insurance premiums for a period of twelve months which approximates $14,000 in aggregate for the twelve months. On October 24, 2022 the Company and its transfer agent were named in an action in the Supreme Court of the State of New York by Acquarlaro Corp. claiming monetary damages and seeking an injunction ordering the Company’s transfer agent to transfer 56 million shares of its common stock allegedly belonging to Acqualaro Corp. to an individual. On October 26, 2022 an amended complaint was filed and on December 5, 2022 the Company filed a motion to dismiss the amended complaint. On April 13, 2023 the Court granted the Company’s motion and dismissed the amended complaint with leave for the plaintiff to refile. On April 26, 2023 the plaintiff filed a second amended complaint against the Company and adding Mr. Pizzino as a defendant. On May 8, 2023 Acqualaro filed a notice of appeal of the decision dismissing the first amended complaint.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
Use of Estimates	Use of Estimates
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable 24,517 0 23,705 0
Software Development for internal use	Software Development for internal use 50,000 5
Concentration of Credit Risk	Concentration of Credit Risk
Recognition of Revenues	Recognition of Revenues Recognition of Revenues The Company’s revenues are derived principally from utilizing new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with medical or age-related conditions. The Company recognizes revenue when it is realized or realizable and earned. For hardware sales, the Company recognizes revenues at a point in time when the product is shipped. Customers are billed on Net 30 terms. For service revenue, the Company recognizes revenues over the term of the service contract and when the services are rendered. For customers who pay several months at a time, the Company records revenues for the month’s services and the balance of funds to deferred revenues, and records the balance of revenues as they become current. Schedule of revenues 3 months ended March 31, 9 months ended March 31, REVENUES 2023 2022 2023 2022 Hardware revenue $ 31,476 $ 5,659 $ 82,201 $ 82,644 Service revenue 162,269 207,323 526,043 736,957 TOTAL REVENUES $ 193,745 $ 212,982 $ 608,244 $ 819,601 The following table discloses changes in unearned revenue for the nine months ended March 31, 2023 and 2022: Schedule of unearned revenue 2023 2022 Balance at beginning of period - June 30, $ 80,880 $ 108,298 Deferred revenue 120,688 168,823 Recognition of unearned revenue (140,095 ) (194,815 ) Balance at the end of the period - March 31, $ 61,473 $ 82,306 Deferral of revenues at March 31, 2023 and March 31, 2022 was $ 61,473 82,306
Deferred Taxes	Deferred Taxes ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information. A tax position that meets this more-likely-than-not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority. The Federal and state income tax returns of the Company for 2022, 2021, and 2020 are subject to examination by the Internal Revenue Service and state taxing authorities for three (3) years from the date filed.
Fair value of financial instruments	Fair value of financial instruments Level 1 Level 2 Level 3 From time to time, our financial instruments include cash, accounts payable and accrued expenses, convertible notes, lines of credit, and credit cards.
Research and Development	Research and Development 0 2,180 209,800 374,484
Basic and Diluted Loss per Common Share	Basic and Diluted Loss per Common Share Schedule of anti-dilutive shares Basis of conversion Dilution 2023 2022 Series A Convertible 688 shares outstanding 1 share A: 2 shares 1,376 1,376 Series B Convertible 9,938 shares outstanding 1 share B: 2 shares 19,876 19,876 Series C Convertible 6,838,889 shares outstanding 1 share C: 10 shares 68,388,890 68,388,890 Series D Convertible 425,000 shares outstanding 1 share D: 10 shares 4,250,000 4,250,000 Series E Convertible 4,000,000 shares outstanding 1 share E: 100 shares 400,000,000 400,000,000 472,660,142 472,660,142 The Company has incurred losses for the past two years, as a result, the basic and diluted share bases will be presented as the same. For the three-month periods ended March 31, 2023 and 2022, the Company incurred losses of ($0.00034) and ($0.00731) per basic share and diluted share, respectively. For the nine months ended March 31, 2023 and 2022, the Company incurred losses of ($0.00118) and ($0.01487) per basic share and diluted share, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes. The update is intended to simplify the current rules regarding the accounting for income taxes and addresses several technical topics including accounting for franchise taxes, allocating income taxes between a loss in continuing operations and in other categories such as discontinued operations, reporting income taxes for legal entities that are not subject to income taxes, and interim accounting for enacted changes in tax laws. The new standard is effective for fiscal years beginning after December 15, 2020; however, early adoption is permitted. The Company does not expect the adoption of this standard have a material impact on the consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from U.S. GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Among other potential impacts, this change is expected to reduce reported interest expense, increase reported net income, and result in a reclassification of certain conversion feature balance sheet amounts from shareholders’ equity to liabilities as it relates to the Company’s convertible senior notes. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS), which is consistent with the Company’s accounting treatment under the current standard. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. The Company early adopted the ASU on July 1, 2022, the beginning of its fiscal year. The Company reviewed all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC, and they did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of revenues	Schedule of revenues 3 months ended March 31, 9 months ended March 31, REVENUES 2023 2022 2023 2022 Hardware revenue $ 31,476 $ 5,659 $ 82,201 $ 82,644 Service revenue 162,269 207,323 526,043 736,957 TOTAL REVENUES $ 193,745 $ 212,982 $ 608,244 $ 819,601
Schedule of unearned revenue	Schedule of unearned revenue 2023 2022 Balance at beginning of period - June 30, $ 80,880 $ 108,298 Deferred revenue 120,688 168,823 Recognition of unearned revenue (140,095 ) (194,815 ) Balance at the end of the period - March 31, $ 61,473 $ 82,306
Schedule of anti-dilutive shares	Schedule of anti-dilutive shares Basis of conversion Dilution 2023 2022 Series A Convertible 688 shares outstanding 1 share A: 2 shares 1,376 1,376 Series B Convertible 9,938 shares outstanding 1 share B: 2 shares 19,876 19,876 Series C Convertible 6,838,889 shares outstanding 1 share C: 10 shares 68,388,890 68,388,890 Series D Convertible 425,000 shares outstanding 1 share D: 10 shares 4,250,000 4,250,000 Series E Convertible 4,000,000 shares outstanding 1 share E: 100 shares 400,000,000 400,000,000 472,660,142 472,660,142

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	Schedule of property, plant and equipment March 31, 2023 June 30, 2022 Furniture $ 29,442 $ 20,000 Office computers, equipment, software 19,689 19,689 Software development costs 45,900 45,900 Dealer Portal 50,000 50,000 Property, plant, and equipment 145,031 135,589 Less accumulated depreciation (103,055 ) (93,938 ) Net property, plant, and equipment $ 41,976 $ 41,651

Notes Payable and Note payabl_2

Notes Payable and Note payable-other (Tables)	9 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of short term notes payable	Schedule of short term notes payable March 31, 2023 June 30, 2022 Notes from subsidiary $ 158,333 $ 174,243 Notes payable – Reg A deposits 138,856 138,856 Short term bridge loan 100,000 100,000 Total Notes Payable $ 397,189 $ 413,099
Schedule of notes payable	Schedule of notes payable March 31, 2023 June 30, 2022 Wells Fargo Loan $ 8,770 $ 8,770 On Deck Loan 139,569 139,569 Susquehanna Salt Loan – 10,500 Prosper Loans 9,994 9,994 Marcus Loan – 5,410 Total Notes from Subsidiary (See Table Above) $ 158,333 $ 174,243

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Schedule of related party transactions	Schedule of related party transactions March 31, June 30, 2023 2022 Related parties – subsidiary $ 177,320 $ 202,875 Due from related parties – (155,800 ) Accrued salaries, bonus, fees 330,932 10,965 Total loans from related parties, net $ 508,252 $ 58,040

Office_Warehouse lease (Tables)

Office/Warehouse lease (Tables)	9 Months Ended
	Mar. 31, 2023
Officewarehouse Lease
Schedule lease cost	Schedule lease cost 2023 2022 Rent expense $ 16,270 $ 12,555
Schedule of future lease payments	Schedule of future lease payments Fiscal Year Ending June 30, 2023 $ 3,975 2024 16,250 2025 16,670 July & August 2025 2,790 Total future minimum lease payments 39,685 Less imputed interest (3,935 ) Total present value of future minimum lease payments $ 35,750
Schedule of balance sheet related leases	Schedule of balance sheet related leases As of March 31, 2023 Operating lease right-of-use assets $ 35,505 Accrued lease liability 13,643 Long-term lease liability 22,107 $ 35,750 As of March 31, 2023 Weighted Average Remaining Lease Term 2.42 Weighted Average Discount Rate 8.44

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details - Schedule of Revenues) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Product Information [Line Items]
Revenues	$ 193,745	$ 212,982	$ 608,244	$ 819,601
Hardware Revenue [Member]
Product Information [Line Items]
Revenues	31,476	5,659	82,201	82,644
Service Revenue [Member]
Product Information [Line Items]
Revenues	$ 162,269	$ 207,323	$ 526,043	$ 736,957

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details - Deferred revenue) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accounting Policies [Abstract]
Balance at beginning of period	$ 80,880	$ 108,298
Deferred revenue	120,688	168,823
Recognition of unearned revenue	(140,095)	(194,815)
Balance at the end of the period	$ 61,473	$ 82,306

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details - Antidilutive information) - shares	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
AntiDilutive Shares	472,660,142	472,660,142
Series A Convertible [Member]
[custom:BasisOfConversion]	688 shares outstanding
[custom:Dilution]	1 share A: 2 shares
AntiDilutive Shares	1,376	1,376
Series B Convertible [Member]
[custom:BasisOfConversion]	9,938 shares outstanding
[custom:Dilution]	1 share B: 2 shares
AntiDilutive Shares	19,876	19,876
Series C Convertible [Member]
[custom:BasisOfConversion]	6,838,889 shares outstanding
[custom:Dilution]	1 share C: 10 shares
AntiDilutive Shares	68,388,890	68,388,890
Series D Convertible [Member]
[custom:BasisOfConversion]	425,000 shares outstanding
[custom:Dilution]	1 share D: 10 shares
AntiDilutive Shares	4,250,000	4,250,000
Series E Convertible [Member]
[custom:BasisOfConversion]	4,000,000 shares outstanding
[custom:Dilution]	1 share E: 100 shares
AntiDilutive Shares	400,000,000	400,000,000

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Aug. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Finite-Lived Intangible Assets [Line Items]
Accounts receivable, net		$ 24,517		$ 24,517		$ 0
Allowance for doubtful accounts		23,705		23,705		0
Deferred revenue		61,473	$ 82,306	61,473	$ 82,306	$ 80,880
Research and Development Expense		$ 0	$ 209,800	$ 2,180	$ 374,484
Software Development [Member]
Finite-Lived Intangible Assets [Line Items]
Purchase of dealer portal	$ 50,000
Depreciated years	5 years

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 41,234,081						$ 41,234,081		$ 39,423,382
Net cash used in operating activities							1,161,977	$ 2,671,141
Stock compensation non-cash expenses							286,600	9,610,554
Net loss	522,141	$ 539,791	$ 748,767	$ 7,367,583	$ 368,985	$ 4,354,735	1,810,699	12,091,303
Cash flow from financing activities							1,117,255	$ 2,443,684
Working capital	$ 2,953,764						$ 2,953,764

Inventory, Prepaid Inventory,_2

Inventory, Prepaid Inventory, and Prepaid Expenses (Details Narrative) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventory, net	$ 33,281	$ 7,064
Prepaid inventories	0	62,040
Prepaid expenses	$ 0	$ 0

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 145,031	$ 135,589
Less accumulated depreciation	(103,055)	(93,938)
Net property, plant, and equipment	41,976	41,651
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	29,442	20,000
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	19,689	19,689
Software Development [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	45,900	45,900
Dealer Portal [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 50,000	$ 50,000

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	Sep. 26, 2022	Mar. 31, 2023	Jun. 30, 2022
Property, Plant and Equipment, Other, Net		$ 41,976	$ 41,651
Used Furniture [Member]
Purchase furniture	$ 9,442
Purchase furniture			36 months

Accounts payable and accrued _2

Accounts payable and accrued expenses and liabilities (Details Narrative) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Payables and Accruals [Abstract]
Accounts payable	$ 66,081	$ 57,940
Accrued liabilities	$ 446,650	$ 374,278

Notes Payable and Note payabl_3

Notes Payable and Note payable-other (Details - Schedule of short term notes) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Debt Disclosure [Abstract]
Notes from subsidiary	$ 158,333	$ 174,243
Notes payable – Reg A deposits	138,856	138,856
Short term bridge loan	100,000	100,000
Total Notes Payable	$ 397,189	$ 413,099

Notes Payable and Note payabl_4

Notes Payable and Note payable-other (Details - Notes payable) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Debt Instrument [Line Items]
Notes Payable	$ 158,333	$ 174,243
Wells Fargo Loan [Member]
Debt Instrument [Line Items]
Notes Payable	8,770	8,770
On Deck Loan [Member]
Debt Instrument [Line Items]
Notes Payable	139,569	139,569
Susquehanna Salt Loan [Member]
Debt Instrument [Line Items]
Notes Payable	0	10,500
Prosper Loans [Member]
Debt Instrument [Line Items]
Notes Payable	9,994	9,994
MARCUS Loan [Member]
Debt Instrument [Line Items]
Notes Payable	$ 0	$ 5,410

Notes Payable and Note payabl_5

Notes Payable and Note payable-other (Details Narrative) - USD ($)		1 Months Ended							3 Months Ended				9 Months Ended		12 Months Ended
	Dec. 05, 2022	Nov. 30, 2021	Oct. 31, 2021	Jul. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Jul. 31, 2020	Sep. 30, 2014	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2022	Aug. 19, 2021	Sep. 30, 2020	Nov. 30, 2016	Mar. 03, 2016	Mar. 01, 2016	Jan. 31, 2015
Debt Instrument [Line Items]
Rate of interest													6.24%
Principle amount repaid																		$ 300,000
Repayment of debt		$ 100,000
Short term notes payable									$ 100,000				$ 100,000				$ 100,000
Interest and accrued interest liability									3,000			$ 3,000	9,000	$ 18,649
Accrued interest payable									85,677				85,677				76,677
Notes payable									158,333				158,333				174,243
Interest Payable									59,624				59,624				49,415
Loan from related party									138,856				138,856				138,856
Interest rate												4%		4%
Proceeds from convertible debt													240,000	$ 0
Number of value issued other									1
Amortized deferred debt issuance costs													15,467	0
Line of credit balance									397,500				397,500				397,500
MCA Cure [Member]
Debt Instrument [Line Items]
Loan payments															$ 47,000	$ 43,875
Reserve fund																			$ 90,875
Medi Pendant [Member]
Debt Instrument [Line Items]
Rate of interest								6.50%
Rate of interest																							$ 5,000
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Interest expense									500			$ 500	1,500	1,000
Interest Payable									12,782				12,782				11,282
B2CF [Member]
Debt Instrument [Line Items]
Convertible notes																					$ 13,750	$ 13,750
BENZA [Member]
Debt Instrument [Line Items]
Convertible notes																					660,000	660,000
BENZA and D2CF [Member]
Debt Instrument [Line Items]
Convertible notes									673,750				$ 673,750				673,750
Leonite Convertible Note [Member]
Debt Instrument [Line Items]
Interest rate													10%
Interest expense									10,839				$ 10,839
Proceeds from convertible debt	$ 250,000
Convertible note face value	1,000,000
Original issue discount	$ 62,500
Maturity date	Mar. 05, 2024
Amortization payments													$ 34,722
Number of shares issued other													15,000,000
Number of value issued other													$ 78,000
Common stocks to be issued													28,064
Legal fees													10,000
Deferred debt issuance costs													59,936
Amortized deferred debt issuance costs									11,987				15,467
Amortized original issue discount									$ 12,500				$ 16,129
Conversion price									$ 0.007				$ 0.007
MCA Cure [Member]
Debt Instrument [Line Items]
Notes payable									$ 0				$ 0				0
On Deck Loan [Member]
Debt Instrument [Line Items]
Notes payable									139,569				139,569				139,569
Susquehanna Salt Loan [Member]
Debt Instrument [Line Items]
Notes payable									0				0				10,500
Chief Executive Officer [Member]
Debt Instrument [Line Items]
Acquisition of convertible notes payable												1,000,000
Two Unaffiliated Investors [Member]
Debt Instrument [Line Items]
Proceed loans			$ 5,000	$ 20,000
Chief Executive Officer [Member]
Debt Instrument [Line Items]
Loan from related party																				$ 50,000
Interest rate																				4%
Regulation A Filing [Member] | Two Unaffiliated Investors [Member]
Debt Instrument [Line Items]
Accepted stock payment					$ 115,000	$ 115,000
Notes payable									138,856				138,856				138,856
Interest expense									2,700			$ 2,700	8,100	$ 8,736
Interest Payable									$ 20,407				$ 20,407				$ 12,307
Private Placement [Member]
Debt Instrument [Line Items]
Aggregate amount																					$ 612,500	$ 612,500
COHEN [Member]
Debt Instrument [Line Items]
Short term bridge loan							$ 500,000
Interest rate							12%
Accrue interest							12%
Minimum [Member]
Debt Instrument [Line Items]
Interest rate													9.24%
Maximum [Member]
Debt Instrument [Line Items]
Interest rate													10.90%

Shareholders_ Deficit (Details

Shareholders’ Deficit (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2022	Mar. 31, 2023
Class of Stock [Line Items]
Preferred stock, shares authorized		25,000,000	25,000,000
Preferred stock, par value		$ 0.0001	$ 0.0001
Common stock, shares authorized		3,000,000,000	3,000,000,000
Common stock, par value		$ 0.0001	$ 0.0001
Contractual bonuses	$ 75,000
Common stock, shares issued		1,493,142,608	1,549,255,108
Common stock, shares outstanding		1,493,142,608	1,549,255,108
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		100,000	100,000
Preferred stock, par value		$ 0.0001	$ 0.0001
Preferred stock, shares issued		688	688
Preferred stock, shares outstanding		688	688
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		62,500	62,500
Preferred stock, par value		$ 0.0001	$ 0.0001
Preferred stock, shares issued		9,938	9,938
Preferred stock, shares outstanding		9,938	9,938
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		6,944,445	6,944,445
Preferred stock, par value		$ 0.0001	$ 0.0001
Preferred stock, shares issued		6,838,889	6,838,889
Preferred stock, shares outstanding		6,838,889	6,838,889
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		4,000,000	4,000,000
Preferred stock, par value		$ 0.0001	$ 0.0001
Preferred stock, shares issued		4,000,000	4,000,000
Preferred stock, shares outstanding		4,000,000	4,000,000
Series E Preferred Stock [Member] | Director 1 [Member]
Class of Stock [Line Items]
Stock issued for services, shares		1,000,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Related Party Transactions [Abstract]
Related parties – subsidiary	$ 177,320	$ 202,875
Due from related parties	0	(155,800)
Accrued salaries, bonus, fees	330,932	10,965
Total loans from related parties, net	$ 508,252	$ 58,040

Related Party Transactions (D_2

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Related Party Transaction [Line Items]
Debt expensed	$ 3,353	$ 6,521	$ 10,209	$ 15,090
Accrued interest	59,624		59,624		$ 49,415
Boapin [Member]
Related Party Transaction [Line Items]
Note payable	$ 170,000		$ 170,000		$ 170,000

Office_Warehouse lease (Details

Office/Warehouse lease (Details) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Officewarehouse Lease
Rent expense	$ 16,270	$ 12,555

Office_Warehouse lease (Detai_2

Office/Warehouse lease (Details 1)	Mar. 31, 2023 USD ($)
Officewarehouse Lease
2023	$ 3,975
2024	16,250
2025	16,670
July & August 2025	2,790
Total future minimum lease payments	39,685
Less imputed interest	(3,935)
Total present value of future minimum lease payments	$ 35,750

Office_Warehouse lease (Detai_3

Office/Warehouse lease (Details 2) - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Officewarehouse Lease
Operating lease right-of-use assets	$ 35,505	$ 0
Accrued lease liability	13,643
Long-term lease liability	22,107	$ 0
Operating lease liability	$ 35,750
Weighted Average Remaining Lease Term	2 years 5 months 1 day
Weighted Average Discount Rate	8.44%

Office_Warehouse lease (Detai_4

Office/Warehouse lease (Details Narrative) - USD ($)	9 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Right of use asset	$ 35,505	$ 0
Lease, Cost	16,270
New Lease Agreement [Member]
Right of use asset	$ 43,058
Minimum [Member]
Lease term	3 years
Maximum [Member]
Lease term	5 years

Other income - settlement (Deta

Other income - settlement (Details Narrative) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Feb. 28, 2022
Other Income and Expenses [Abstract]
Attorney costs			$ 105,125
Settlement income	$ 19,500	$ 0